Logo Image
|Podcasts|January 6, 2011

Biosimilars in the US

Biosimilars in the US

The Food and Drug Administration recently held a two-day public hearing as it prepares to put into place regulations for the approval of generic versions of biological products. PharmaNet Consulting executives, William M. Egan, PhD, Vice President, and Jeffrey J. Freitag, MD, Senior Vice President, provide an overview of the meeting; the current market temperature of biologic development programs in the US; and what sponsors can expect in lieu of a formal FDA guideline.

Jeffrey J. Freitag, MD, Senior Vice President

William M. Egan, PhD, Vice President

 

Related to this article

View more
The Human Side of Clinical Trials: Why Fuzzy Mental Models Undermine Clinical Trial Execution
The Human Side of Clinical Trials: Why Fuzzy Mental Models Undermine Clinical Trial Execution
In Episode 3 of The Human Side of Clinical Trials, hosts Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., speak with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about why a well-written protocol doesn’t always translate into consistent execution, and how designing for the way people actually think and learn can reduce site burden and the need for costly unlearning.
Read more
© putilov_denis - © putilov_denis - stock.adobe.com
Real-Time Clinical Trials Depend on a Scalable EHR-to-EDC Connection
Real-time clinical trials require standardized digital data capture at the point of care through scaled eSource-EDC-EHR integration, but progress stalls because competing standards lack regulatory enforcement and one-off system integrations cannot scale beyond single studies without industry-wide alignment and legal clarity on data ownership.
Read more